119th Congress
H.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Neal P. Dunn(R-FL)
- Introduced
- Mar 5, 2025
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce
- Official text
- Introduced in House · Congress.gov page
Cosponsors (1)
Original cosponsors (1)
- Kevin Mullin (D-CA)
Summary
Summary by the Congressional Research Service· describes the “Introduced in House” version
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Roll-call votes
No recorded votes on this bill.
Actions
- Mar 5, 2025 · House
Referred to the House Committee on Energy and Commerce. - Mar 5, 2025
Introduced in House